174 related articles for article (PubMed ID: 36379410)
1. Efficacy of lanadelumab in angioedema due to acquired C1 inhibitor deficiency.
Suffritti C; Sartorio S; Berra S; Janu VP; Caccia S; Zanichelli A
J Allergy Clin Immunol Pract; 2023 Mar; 11(3):963-965.e1. PubMed ID: 36379410
[No Abstract] [Full Text] [Related]
2. Efficacy of lanadelumab in acquired angioedema with C1-inhibitor deficiency.
Belbézier A; Boccon-Gibod I; Bouillet L
J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2490-2491. PubMed ID: 33556593
[No Abstract] [Full Text] [Related]
3. Effectiveness of lanadelumab in patients with hereditary angioedema with normal C1 inhibitor and FXII mutation.
Bouillet L; Bocquet A; Belbezier A; Boccon-Gibod I
Ann Allergy Asthma Immunol; 2021 Sep; 127(3):391-392. PubMed ID: 34082125
[No Abstract] [Full Text] [Related]
4. Letter to the editor: network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema.
Schlueter M; Nestler-Parr S
J Comp Eff Res; 2024 May; 13(5):e230165. PubMed ID: 38545965
[No Abstract] [Full Text] [Related]
5. Successful Use of Recombinant Human C1-INH in a Patient with Acquired Angioedema due to C1 Inhibitor Deficiency and an Unusually High Titer of Anti-C1-Inhibitor Autoantibodies.
Jesenak M; Brndiarova M; Banovcin P; Varga L; Farkas H
J Investig Allergol Clin Immunol; 2021 Jun; 31(3):255-256. PubMed ID: 32732186
[No Abstract] [Full Text] [Related]
6. Lanadelumab for the prevention of hereditary angioedema attacks: A real-world UK audit.
Dorr AD; Chopra C; Coulter TI; Dempster J; Dziadzio M; El-Shanawany T; Garcez T; Gompels M; Herriot R; Jain R; Levi M; Lorenzo L; Makki I; Mapazire E; Murng SHK; Noorani S; Savic S; Steele CL; Symons C; Tarzi M; Yong PFK; Kiani-Alikhan S
Allergy; 2023 May; 78(5):1369-1371. PubMed ID: 36510404
[No Abstract] [Full Text] [Related]
7. New drugs to treat hereditary angioedema.
Scheinfeld N
Skinmed; 2013; 11(6):357-9. PubMed ID: 24517042
[No Abstract] [Full Text] [Related]
8. [Hereditary angioedema due to C1-esterase inhibitor deficiency : novel approaches].
Stehlin F; Ribi C
Rev Med Suisse; 2020 Apr; 16(689):675-678. PubMed ID: 32270933
[TBL] [Abstract][Full Text] [Related]
9. Three new drugs for hereditary angioedema.
Med Lett Drugs Ther; 2010 Aug; 52(1345):66-7. PubMed ID: 20724964
[No Abstract] [Full Text] [Related]
10. Lanadelumab: First Global Approval.
Syed YY
Drugs; 2018 Oct; 78(15):1633-1637. PubMed ID: 30267321
[TBL] [Abstract][Full Text] [Related]
11. Medical algorithm: Management of C1 inhibitor hereditary angioedema.
Caballero T; Cabañas R; Pedrosa M
Allergy; 2022 Mar; 77(3):1060-1063. PubMed ID: 34587298
[No Abstract] [Full Text] [Related]
12. Recombinant human C1 esterase inhibitor as prophylactic treatment in idiopathic non-histaminergic angioedema.
Alizadeh Aghdam M; Hofman ZLM; Meertens M; Lebens A; Hack CE; Knulst AC; Maas C; Röckmann H
Allergy; 2022 Dec; 77(12):3673-3676. PubMed ID: 35837765
[No Abstract] [Full Text] [Related]
13. A case of normal C1 esterase inhibitor hereditary angioedema successfully treated with berotralstat.
Kelbel T
Ann Allergy Asthma Immunol; 2022 Apr; 128(4):462-463. PubMed ID: 35063629
[No Abstract] [Full Text] [Related]
14. Hereditary Angioedema.
Busse PJ; Christiansen SC
N Engl J Med; 2020 Mar; 382(12):1136-1148. PubMed ID: 32187470
[No Abstract] [Full Text] [Related]
15. Lanadelumab for the prevention of attacks in hereditary angioedema.
Valerieva A; Senter R; Wu MA; Zanichelli A; Cicardi M
Expert Rev Clin Immunol; 2019 Dec; 15(12):1239-1248. PubMed ID: 31721602
[No Abstract] [Full Text] [Related]
16. Recombinant human C1 esterase inhibitor as short-term prophylaxis in patients with hereditary angioedema.
Valerieva A; Staevska M; Jesenak M; Hrubiskova K; Sobotkova M; Zachova R; Hakl R; Andrejevic S; Suiter T; Grivcheva-Panovska V; Karadza-Lapic L; Soteres D; Shapiro R; Rumbyrt J; Tachdjian R; Mehta V; Hsu FI; Zanichelli A
J Allergy Clin Immunol Pract; 2020 Feb; 8(2):799-802. PubMed ID: 31437566
[No Abstract] [Full Text] [Related]
17. Benefits of hydroxychloroquine in the treatment of a patient with angioedema due to acquired C1 inhibitor deficiency.
Vincent D; Ponard D; Fiorella S; Drouet C
Ann Allergy Asthma Immunol; 2015 Jan; 114(1):68-70. PubMed ID: 25457864
[No Abstract] [Full Text] [Related]
18. A review of kallikrein inhibitor lanadelumab in hereditary angioedema.
Hwang G; Johri A; Ng S; Craig T
Immunotherapy; 2019 Aug; 11(11):937-944. PubMed ID: 31234673
[TBL] [Abstract][Full Text] [Related]
19. Lanadelumab Efficacy, Safety, and Injection Interval Extension in HAE: A Real-Life Study.
Buttgereit T; Vera C; Weller K; Gutsche A; Grekowitz EM; Aykanat S; Wahn V; Krüger R; Maurer M; Magerl M
J Allergy Clin Immunol Pract; 2021 Oct; 9(10):3744-3751. PubMed ID: 34023564
[TBL] [Abstract][Full Text] [Related]
20. Lanadelumab (Takhzyro) for prevention of hereditary angioedema.
Med Lett Drugs Ther; 2021 Mar; 63(1619):e41-e42. PubMed ID: 33755657
[No Abstract] [Full Text] [Related]
[Next] [New Search]
